(Q37646785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

review article

1 reference

title

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

Helicobacter pylori infectious disease

13 February 2020

main subject

Helicobacter pylori

0 references

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Chun-Jung Lin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

29-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19968574%20AND%20SRC:MED&resulttype=core&format=json

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Eradication therapy for Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Review article: the clinical pharmacology of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

The pharmacology of the gastric acid pump: the H+,K+ ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

The choice of proton pump inhibitor: does it matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Comparison of five antisecretory agents acting via gastric H+/K+-ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Review article: rabeprazole-based therapy in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Rabeprazole: a review of its use in acid-related gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Zonation of hepatic cytochrome P-450 expression and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

The CYP2C19 enzyme polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pharmacokinetic considerations in the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

CYP2C19 polymorphism and proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Transcatheter coil embolotherapy: a safe and effective option for major colonic haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Review article: the treatment of refractory Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

High eradication rates of Helicobacter pylori with a new sequential treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Seven-day therapy for Helicobacter pylori in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251

Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903386251